Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valbenazine - Neurocrine Biosciences

Next Previous
Drug Profile

Valbenazine - Neurocrine Biosciences

Alternative Names: DYSVAL; DYSVAL capsules 40mg; INGREZZA; INGREZZA SPRINKLE; MT 5199; NBI-98854; REMLEAS; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-Biosciences

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences; Tanabe Pharma Corporation
  • Class 3-ring heterocyclic compounds; Amino acids; Antipsychotics; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chorea; Tardive dyskinesia
  • Phase III Cerebral palsy; Schizophrenia
  • Phase II Gilles de la Tourette's syndrome

Most Recent Events

  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 06 Oct 2025 Updated efficacy and adverse events data from the phase III KINECT-HD2 trial in Chorea released by Neurocrine Biosciences
  • 05 Apr 2025 Updated efficacy and adverse events data from the phase III KINECT-HD2 trial in Chorea presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top